To address variations in marker expression profiles due to different NSCLC subtypes and genetic backgrounds, and their potential impact on the effectiveness of the capture approach, we evaluated the expression of EpCAM, PD-L1, EGFR, and ofCS (rVAR2 binding target) across various cell lines. This evidence concerns the gene EGFR and non-small cell lung carcinoma.